

Impact of Baseline Year on Prospective Payment System Payments Under the Quality Improvement Program Andrew Barba¹; Michael Phillips¹; Randy Smith¹; Joe Weldon, MBA²; LeAnne Zumwalt¹; Mahesh Krishnan, MD, MBA, MPH^{2*}

Introduction

- In 2011, the Centers for Medicare and Medicaid Services (CMS) issued a final rule creating the Quality Incentive **Program (QIP) to determine payment for end-stage renal** disease (ESRD) patients' dialysis treatments and medications starting in 2012.¹
- The 2012 payment QIP uses 3 weighted quality measures to generate a Total Performance Score (TPS) for dialysis facilities:¹
- Percent of patients with hemoglobin (Hb) <10 g/dL
- Percent of patients with Hb >12 g/dL
- Percent of patients with urea reduction ratio (URR) \geq 65%.

Facility TPS Calculation	TPS Tiers
% of Patients with	% of reimbursement
Hb <10 g/dL (50% 10 pts)	30-26 points 100%
Hb >12 g/dL (25% 10pts)	21-25 points 99.5%
<u>URR ≥65% (25% 10 pts)</u>	16-20 points 99.0%
Max total 10 pts	11-15 points 98.5%
10 pts x 3 =30 pts	0-10 points 98.0%

- The TPS compares a facility's 2010 quality measures to the least stringent benchmark of either:
- The facility's performance in 2007 (base year) or
- The 2008 national average.
- We estimated QIP performance for DaVita dialysis centers using fiscal year (FY)10 Medicare claims data.

Methods

- Mean Hb and median URR were calculated using claim-reported values according to the QIP.¹ ESRD patients were qualified for Hb measurement if they have 4 or more claims in the calendar year; claims were disqualified if:
- Begin date was <90 days of the patient's first date of dialysis
- No erythopoiesis stimulating agent (ESA) claim
- No Hb value, or if the Hb value was between 5 and 20 g/dL.


Medicare Claims by Reported Hb Level

% of	Me
70%	
60%	
50%	_
40%	_
30%	
20%	_
10%	_
0%	


- 100%
- 90%
- 80%
- 70%
- 60%
- 50%
- 40%
- 30%
- 20%
- 10%
- 0%

Results

edicare claims



Centers Meeting Hb <10 g/dL Standard



*N=1,275 centers with sufficient data in 2007, 2008, 2009, and 2010. Standard is equal to the least stringent of baseline year performance or 2008 national average.

Higher % Patients with Mean Hb <10 g/dL Over Time

Cumulative % of facilities % Male -2007 DFC -FY08 Claims - FY09 Claims -FY10 Claims 2% 3% 7% 0% 5% 6%

% of patients with mean Hb <10 g/dL

Demographics

Age in years Vintage in ye **Body Mass I** % Diabetic Race % African A Hispanic Asian, Pa **Native An** Unknown

** N=85,601 Medicare patients

1. DaVita, Denver, CO, United States; 2. DaVita Clinical Research, Minneapolis, MN, United States

Baseline Year	% Facilities Meeting Standard *
2007	62.1%
2008	65.8%
2009	71.1%

	Study Population**
s, mean (SD)	62.2 (15.1)
	54.3
ears, mean (SD)	4.8 (3.8)
Index, mean (SD)	20.8 (7.2)
	44.3
merican	38.7
	14.6
acific Islander	3.7
nerican	1.6
ו	0.1

Summary

References

1. Medicare Program; End-Stage Renal Disease Quality Incentive Program. *Fed Regist* 2011;76(3):623-46.

Our sincere appreciation goes to the teammates in more than 1,600 DaVita clinics who work every day to take care of patients but also to ensure the extensive data collection on which our work is based. We thank DaVita Clinical Research[®] (DCR[®]), and specifically acknowledge Donna Jensen, PhD of DCR for editorial contributions in preparing this poster. DCR is committed to advancing the knowledge and practice of kidney care.

*Correspondence: <u>Mahesh.Krishnan@davita.com</u>

Poster available at: <u>www.davitaclinicalresearch.com/directory.asp</u>

American Society of Nephrology, Philadelphia, PA November 10-13, 2011

• Changes in science, regulatory policy and practice regarding anemia management in ESRD patients have taken place since 2007, the baseline year for the 2012 QIP payment year.

Year-to-year differences in facility-level Hb performance have resulted, and the proportion of centers adversely affected by the <10 g/dL QIP measure is accordingly substantial.

 Discordance between 2012 QIP payment metrics, as currently formulated, and current science, regulation and practice in anemia management, highlight the need for prospective payment quality measures that preserve contemporary validity.